EICHORPublic-registry site landscape for NCT03844932, “A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis”, a Colitis, Ulcerative study sponsored by Sublimity Therapeutics Holdco Limited. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03844932 (registry record) |
| Study title | A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis |
| Official title | A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis |
| Sponsor | Sublimity Therapeutics Holdco Limited |
| Condition(s) | Colitis, Ulcerative |
| Phase | PHASE2 |
| Listed sites | 89 |
| Site countries | United States, Belarus, Bulgaria, Canada, France, Germany, Hungary, Ireland, Israel, Italy, Poland, Romania |
Patient-friendly overview of this study: eichor.com/study/NCT03844932.
Eichor generates a preliminary site-risk snapshot for NCT03844932 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Colitis, Ulcerative trials
← Eichor home · All tracked trials · Colitis, Ulcerative studies · Weekly briefs
